Status
Conditions
Treatments
About
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine)designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
-There are no exclusion criteria for this study.
1,100 participants in 1 patient group
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal